Equities

Fulgent Genetics Inc

Fulgent Genetics Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)17.62
  • Today's Change0.67 / 3.95%
  • Shares traded134.79k
  • 1 Year change-35.88%
  • Beta1.4355
Data delayed at least 15 minutes, as of Nov 22 2024 17:03 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform1
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for Fulgent Genetics Inc have a median target of 27.00, with a high estimate of 30.00 and a low estimate of 22.00. The median estimate represents a 59.29% increase from the last price of 16.95.
High77.0%30.00
Med59.3%27.00
Low29.8%22.00

Earnings history & estimates in USD

On Nov 08, 2024, Fulgent Genetics Inc reported 3rd quarter 2024 earnings of 0.31 per share. This result exceeded the -0.150 consensus loss of the 3 analysts covering the company and outperformed last year's 3rd quarter results by 0.70.
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate+106.67%
Fulgent Genetics Inc reported annual 2023 losses of -0.41 per share on Feb 28, 2024.
Average growth rate+1,568.27%
More ▼

Revenue history & estimates in USD

Fulgent Genetics, Inc. had 3rd quarter 2024 revenues of 71.74m. This bettered the 71.72m consensus of the 3 analysts covering the company. This was 8.43% above the prior year's 3rd quarter results.
Average growth rate-3.53%
Fulgent Genetics, Inc. had revenues for the full year 2023 of 289.21m. This was 53.27% below the prior year's results.
Average growth rate+310.23%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.